Connect Biopharma Holdings (CNTB) Receivables - Other (2020 - 2026)

Connect Biopharma Holdings (CNTB) has reported Receivables - Other for 7 consecutive years, with $32000.0 the latest figure, recorded in Q1 2026.

• Quarterly Receivables - Other fell 80.84% year-over-year to $32000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (down 80.84% YoY) and the FY2025 annual result came in at $148000.0, down 43.51% from the prior year.
• Receivables - Other slipped to $32000.0 in Q1 2026 per CNTB's latest filing, from $148000.0 in the prior quarter.
• Over the last five years, Receivables - Other for CNTB reached as high as $7.1 million in Q2 2022 and fell as low as $32000.0 in Q1 2026.
• A 5-year average of $1.7 million and a median of $262000.0 in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2023 — Receivables - Other retreated 7.3% — and 2024, when it slumped 95.66%.
• Year by year, Receivables - Other stood at $3.3 million in 2022, then sank by 89.34% to $351000.0 in 2023, then declined by 25.36% to $262000.0 in 2024, then plunged by 43.51% to $148000.0 in 2025, then slumped by 78.38% to $32000.0 in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $32000.0, $148000.0, and $157000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.